Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Novartis Pharmaceuticals
Scientific Title
A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer